Skip Navigation
  Print Page

How is hypoparathyroidism treated?

Skip sharing on social media links
Share this:

The goal of treatment for hypoparathyroidism is to restore the body’s calcium, magnesium, and phosphorus levels in the blood and urine to normal levels. This may be challenging, especially with conventional therapy.

The only therapies that are approved by the Food and Drug Administration (FDA) for hypoparathyroidism (from any cause) are synthetic forms of vitamin D and calcium and magnesium supplements.

Some individuals with hypoparathyroidism are encouraged to eat foods high in calcium such as dairy products, breakfast cereals, fortified orange juice, and green, leafy vegetables.1

Hypoparathyroidism is one of the few hormone deficiency diseases that are not usually treated with the missing hormone. However, greater availability of various forms of parathyroid hormone (PTH) has led to several studies of investigational drugs for this condition.2

Studies from the NICHD and other research centers have shown the investigational drugs PTH 1-34 or PTH 1-84 injections work well as an alternative to conventional therapy. Research shows that PTH 1-34 given as an injection twice daily or through a pump (originally designed for diabetics) is an effective way to treat most forms of congenital hypoparathyroidism.3,4,5


  1. University of Maryland Medical Center. (2011). Hypoparathyroidism. Retrieved June 22, 2012, from http://www.umm.edu/altmed/articles/hypoparathyroidism-000091.htm External Web Site Policy [top]
  2. Sikjaer, T., Rejnmark, L., & Mosekilde, L. (2011). PTH treatment in hypoparathyroidism. Current Drug Safety, 6, 89-99. [top]
  3. Winer, K. K., Yanovski, J. A., & Cutler, G. B., Jr. (1996). Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism: results of a randomized crossover trial. Journal of the American Medical Association, 276, 631-636. [top]
  4. Winer, K. K., Yanovski, J. A., Sarani, B., & Cutler, G. B., Jr. (1998). A randomized, crossover trial of once-daily vs twice-daily human parathyroid hormone 1-34 in the treatment of hypoparathyroidism. Journal of Clinical Endocrinology and Metabolism, 83, 3480-3486. [top]
  5. Winer, K. K., Zhang, B., Shrader, J. A., Peterson, D., Smith, M., Albert, P. S., et al. (2012). Synthetic human parathyroid hormone 1-34 replacement therapy: A randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism. Journal of Clinical Endocrinology and Metabolism, 97, 391-399. [top]

​​
Last Updated Date: 07/30/2013
Last Reviewed Date: 07/05/2013
Vision National Institutes of Health Home BOND National Institues of Health Home Home Storz Lab: Section on Environmental Gene Regulation Home Machner Lab: Unit on Microbial Pathogenesis Home Division of Intramural Population Health Research Home Bonifacino Lab: Section on Intracellular Protein Trafficking Home Lilly Lab: Section on Gamete Development Home Lippincott-Schwartz Lab: Section on Organelle Biology